clinical trial · NCT06259526
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Tasly Pharmaceutical Group Co., Ltd·phase2·completed·n = 267
DepressionPlacebo groupJS1-1-01 low-dose groupJS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsulesJS1-1-01 high-dose groupActive drug group
brief summary
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
started
Dec 26, 2023
primary completion
Oct 23, 2024
completion
Oct 23, 2024
last updated
Nov 19, 2025
official title
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol